logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
8/3/2022 7:04:34 AM Alnylam Reports Positive Topline Results From APOLLO-B Study Of Patisiran In ATTR Amyloidosis With Cardiomyopathy
7/28/2022 8:05:02 AM Alnylam Pharma Q2 Loss Per Share $2.29; Non-GAAP Loss Per Share $2.03
6/9/2022 7:04:25 AM Alnylam Reports Positive Topline Results From Phase 2 Study Of Cemdisiran For IgA Nephropathy
5/24/2022 7:04:09 AM Alnylam Presents New Results From ILLUMINATE-C Phase 3 Study Of Lumasiran In Advanced Primary Hyperoxaluria Type 1
5/18/2022 8:04:41 AM Alnylam : Canada Authorizes OXLUMO For Treatment Of Primary Hyperoxaluria Type 1 To Lower Urinary Oxalate Levels
4/28/2022 8:05:22 AM Alnylam Pharmaceuticals Q1 Net Loss Widens To $240.3 Mln From $200.3 Mln Last Year
4/5/2022 4:07:55 PM Alnylam Announces Retirement Of Steven Paul From Board Of Directors
4/4/2022 7:37:42 AM Alnylam : FDA Extends Review Timeline Of NDA For Vutrisiran To July 14, 2022; No Additional Clinical Data Requested